Clinical Trial Update: Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating GC1008 (fresolimumab), a TGF-beta antagonist, for safety and preliminary efficacy in renal cell carcinoma and malignant melanoma; study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Renal Cell Carcinoma

Drugs mentioned

• GC1008 (fresolimumab)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Carcinoma, Renal Cell, Melanoma | Phase 1 | Status: COMPLETED